Although anti-IL-1 agents such as anakinra and canakinumab are not recommended in COVID-19 pneumonia according to current guidelines [51], their effectiveness in reducing cytokine storms may make them suitable candidates as alternatives to tocilizumab and baricitinib in patients with severe COVID-19 and high risk of CAPA [33,70]. Here, IL1A is linked to episodic ataxia type 2.